- Conditions
- Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
- Interventions
- Pozelimab/Cemdisiran
- Combination Product
- Lead sponsor
- Austin Neuromuscular Center
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 5,568
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
- Interventions
- VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Cleveland, Ohio
- Conditions
- Advanced Cancer, Refractory Cancer, Tumor Gastric
- Interventions
- PCS6422 and capecitabine
- Drug
- Lead sponsor
- Processa Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Omaha, Nebraska • New Brunswick, New Jersey • Santa Fe, New Mexico + 3 more
- Conditions
- Hepatitis C
- Interventions
- SOF/VEL/VOX, SOF/VEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 47
- States / cities
- Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Photodynamic Therapy
- Procedure
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Interventions
- Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
- Conditions
- Systemic Sclerosis
- Interventions
- Belimumab, Mycophenolate Mofetil, Placebo Infusion
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- GU Research Network, LLC
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- salmonella VNP20009, cefixime, ceftriaxone sodium, ciprofloxacin, trimethoprim-sulfamethoxazole
- Biological · Drug
- Lead sponsor
- Vion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Dallas, Texas
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- HIV
- Interventions
- Emtricitabine and tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Philadelphia Fight
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Asthma
- Interventions
- Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 621 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 58
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
- Drug · Other
- Lead sponsor
- Razor Genomics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 18
- States / cities
- Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more
- Conditions
- Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)
- Interventions
- Ruxolitinib, LBP- MARCO
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Cystic Fibrosis
- Interventions
- LUM/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 17
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
- Conditions
- Fragile X Syndrome
- Interventions
- AFQ056, Placebo, Language Intervention
- Drug · Other
- Lead sponsor
- Elizabeth Berry-Kravis
- Other
- Eligibility
- 32 Months to 6 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 14
- States / cities
- Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
- Interventions
- Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
- Drug
- Lead sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
- Individual
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Advanced Solid Tumor
- Interventions
- BGB-58067, BG-89894, Standard of Care Therapy, RAS(ON) Inhibitors
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Los Alamitos, California • Los Angeles, California • Celebration, Florida + 8 more
- Conditions
- Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
- Interventions
- Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
- Device
- Lead sponsor
- HepQuant, LLC
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer
- Interventions
- Ixabepilone, Capecitabine, Motesanib
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Liver Cancer
- Interventions
- bevacizumab, chemotherapy, embolization therapy, hepatic artery infusion
- Biological · Drug · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Gastric Cancer, Stomach Cancer
- Interventions
- Paclitaxel, Carboplatin, Dexamethasone, Diphenhydramine, Famotidine, Palonosetron, 3D conformal or intensity modulated radiotherapy, Surgical resection, Adjuvant Chemotherapy
- Drug · Radiation · Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Buprenorphine HCl/Naloxone HCl
- Drug
- Lead sponsor
- NanoSHIFT LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas